Cechini et al. discovered that the combination of temozolomide and Olaparib was well tolerated by patients suffering from colorectal cancer, and that it did demonstrate anticancer effectiveness in a subgroup of patients whose tumors showed MGMT promoter hypermethylation, reduced MGMT protein expression, and enhanced CD8+ effector TILs. Here, MGMT is linked to colorectal cancer.